| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 | 425 |
| 12 Nov 2026 |
8-K: Other Events
On November 7, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, and Slate Medicines, Inc., or Slate, entered into an asset purchase agreement providing for the sale of Fulcrum’s early-stage fetal hemoglobin, or HbF, assets to an unaffiliate... |
| 04 Nov 2026 | EFFECT |
| 04 Nov 2026 | 424B3 |
| 03 Nov 2026 | S-4/A |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 20 Oct 2026 | S-4/A |
| 08 Oct 2026 | S-4/A |
| 02 Sep 2026 | 144 |
| 02 Sep 2026 | S-4 |
| 17 Aug 2026 | 425 |
| 17 Aug 2026 | 425 |
| 17 Aug 2026 | 425 |
| 17 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 16, 2026, by and among Slate Medicines, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (eac... |
Loading...